Recently, Hunan Mabgeek Biotech Co., Ltd. received feedback from the China Securities Regulatory Commission (CSRC) regarding its overseas listing filing. The specific feedback requires the company to provide supplementary explanations on the following matters, with lawyers required to conduct verification and provide clear legal opinions:

1. Regarding equity changes: (1) Please explain the pricing basis for each capital increase and equity transfer of the company and its predecessor Mabgeek Limited, whether capital contributions were actually paid, whether there are situations of unfulfilled capital contribution obligations or defective contribution methods, and provide clear conclusive opinions on whether the equity changes were legal and compliant; (2) Please explain the progress of industrial and commercial registration procedures for partner changes of controlling shareholder Maicon Partners.

2. According to the legal opinion, the company's current direct shareholders do not engage in proxy holding; please conduct verification in accordance with the verification requirements regarding share proxy holding under "Regulatory Rule Application Guidelines - Overseas Issuance and Listing Category No. 2."

3. The business scope of the company and its subsidiaries includes "medical research and experimental development." Please explain whether relevant business is actually conducted and specific operational conditions, whether necessary qualifications and permits have been obtained, and whether the company's business scope and actual business operations involve foreign investment prohibited or restricted areas.

4. Please explain the progress of state shareholder identification procedures for Zhangjiang Technology Investment.

5. Regarding this issuance and listing and "full circulation": (1) Please explain the expected fundraising scale after full exercise of the over-allotment option; (2) Please explain whether the shares held by shareholders intending to participate in "full circulation" are subject to pledge, freezing, or other defective rights.

6. Please explain whether the patent application rights ownership dispute case between the company and 3SBio has caused significant adverse impact on the company's business operations and whether it constitutes a substantial obstacle to the company's current issuance and listing.

On July 14, Hunan Mabgeek Biotech submitted its main board listing application to the Hong Kong Stock Exchange. Founded in 2016, Mabgeek Biotech focuses on developing innovative therapies for allergic and autoimmune diseases such as atopic dermatitis, asthma, and nodular prurigo through biological preparation technology.